Navigation Links
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
Date:5/6/2009

CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bordeaux. The contract covers the development, production and marketing of a paediatric beta-blocker for the treatment of severe infantile haemangioma with the intention of obtaining NDA-approval (New Drug Application) both for Europe and the USA. Patents were also applied for in this indication.

The efficacy of beta-blockers on haemangioma was discovered by Dr. Christine Leaute- Labreze, dermatologist in Pr. Alain Taieb's department in Bordeaux. "Effectiveness of this treatment has been demonstrated in several hundred children throughout the world. Rigorous clinical trials are, however, yet to be conducted to ascertain the efficacy and tolerance of this new therapeutic strategy, hence this agreement with Pierre Fabre Dermatologie, which would ensure safety and availability of the treatment."

This therapeutic breakthrough has been widely talked about, not only during scientific conferences but also through professional and general-interest press.

"This is a major discovery that will bring true therapeutic advance to patients affected by this highly apparent disease, which can be very severe and can have a strong impact on their quality of life and that of their parents. For this reason, we are highly honoured to have signed this agreement with the University of Bordeaux on severe haemangioma," specifies Jacques Fabre, General Manager of Pierre Fabre Dermocosmetique.

About haemangioma:

Infantile haemangioma refers to a vascular tumour highly prevalent in infants, with a 10% concurrency rate. Haemangioma occurs in the first months of life and is located on the face in 60% of cases
'/>"/>

SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
2. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
3. Evotec Starts Phase II in Smoking Cessation with EVT 302
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 Publicis Healthcare Communications Group ... the organization has won a total of 20 awards ... LifeBrands was honored with a Silver Award and 11 ... eight Awards of Excellence. , The Annual Rx ... and promotion. The Awards provide a forum for the ...
(Date:11/26/2014)... November 26, 2014 In keeping with ... customers a bevy of last-minute Thanksgiving savings. The company ... offers across all product lines this holiday weekend as ... Thanksgiving, Black Friday, and Cyber Monday are right around ... thanks to both loyal customers and those looking to ...
(Date:11/26/2014)... On January, 14, 2015, UMBC’s Biotechnology Graduate ... community to the UMBC campus for a discussion on ... Society, will take place from 9 a.m. to 4 ... discussion, presentations and workshops, the free symposium will highlight ... in the industry and the future of protein research. ...
(Date:11/26/2014)... SonaCare Medical, a leading manufacturer ... recently participated in the American Urology Association’s (AUA) ... Key opinion leaders in urology presented on the ... renal masses while attendees had the opportunity to ... hands-on labs. Attendees at the Los Angeles, CA ...
Breaking Biology Technology:Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3
... ,, A review of products for signal ... Activation of Signal Transduction Pathways with,PathDetect ... Mary Buchanan Chao-Feng Zheng ,Stratagene , ... such as,growth, differentiation, and coordination of cellular activities. ...
... streamlined and reliable method to obtain high-quality ... Basehore ,Stratagene , The StrataPrep ... quick, and reliable purification of bacteriophage single-stranded ... phage lysate exceeds the yield,obtained with the ...
... Preadipocytes and Differentiated Adipocytes ,,, A ... , Yuan-Di C. Halvorsen ,Zen-Bio, Inc. , ... , Regis Saladin , Ligand Pharmaceuticals ... , Stratagene introduces new tools to facilitate ...
Cached Biology Technology:Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 2Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 3Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 4Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 5Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 6Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 7Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 8Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 9Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 10Purified Single-Stranded M13 DNA for Automated Sequencing 2Purified Single-Stranded M13 DNA for Automated Sequencing 3Human Primary Preadipocytes and Differentiated Adipocytes 2Human Primary Preadipocytes and Differentiated Adipocytes 3Human Primary Preadipocytes and Differentiated Adipocytes 4Human Primary Preadipocytes and Differentiated Adipocytes 5Human Primary Preadipocytes and Differentiated Adipocytes 6
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
(Date:11/2/2014)... 2014)—In support of a bold quest to rid the ... Foundation today announced an award of US$156 million to ... in building new vaccines that will interrupt the cycle ... to zero" agenda. Such vaccines would ensure that parasite ... an "immunological bed net." , This approach to ...
(Date:11/2/2014)... and bump into a biologist . . . , While ... sketch, researchers have taken this premise and applied it to ... in the rising oceans of genomic data. , In this ... studies are publishing at a dizzying rate. The challenge is ... the noise (and there is no shortage of noise). , ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... have believed that eating large amounts of protein made it ... the winner of five consecutive Olympic wrestling championships in the ... he built his crushing strength in part by consuming 20 ... go to such extremes, but Milo,s legacy survives in the ...
... cells, which make up 45 percent of blood, normally take ... side. But they can sometimes deform into an asymmetrical slipper ... explore how fluid flow might be responsible for this deformation, ... flow. The insights could help understand the mechanisms involved in ...
... 26, 2009 Results of an important new study ... at the time of cataract surgery increases a nutritional ... the development and/or progression of age-related macular degeneration (AMD). ... from the Macular Pigment Research Group at the Waterford ...
Cached Biology News:Moderate amounts of protein per meal found best for building muscle 2Blue light-filtering increases macular pigment, may protect against age-related vision loss 2Blue light-filtering increases macular pigment, may protect against age-related vision loss 3Blue light-filtering increases macular pigment, may protect against age-related vision loss 4